Inozyme Targets Underserved Mineralization Disorders Market With First-In-Class Enzyme Therapy

 
• By Ayisha Sharma

Emerging Company Profile: Fresh from a $73m follow-on offering last year, the US biotech is readying its lead asset for a pivotal trial in ultra-rare but debilitating mineralization disorders that affect infants and children.  

Emerging Company Profile: Inozyme Pharma
ENPP1 Deficiency Can Cause Arterial Calcification And Eventual Death • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs